Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
ZNTL
ZNTL
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ZNTL News
Zentalis' Azenosertib Accepted for ASCO Presentation
1h ago
Newsfilter
Zentalis Unveils New Data, Paving New Directions in Cancer Treatment
3d ago
Newsfilter
Zentalis Selects 400 mg Dose for Ovarian Cancer Treatment
Apr 10 2026
stocktwits
Zentalis Grants Stock Options to New Employees
Apr 01 2026
Newsfilter
Zentalis Pharmaceuticals Reports FY 2025 Financial Results
Mar 26 2026
seekingalpha
Oncolytics Biotech Advances Pelareorep for Anal Cancer with 29% Response Rate
Jan 12 2026
PRnewswire
Oncolytics Biotech Advances Pelareorep for Anal Cancer with 29% Response Rate
Jan 12 2026
Newsfilter
Zentalis Pharmaceuticals (ZNTL) Surges 17.65% as Investors Renew Interest
Jan 12 2026
NASDAQ.COM
China SXT Pharmaceuticals Launches AI Initiative, Stock Rises 13.6%
Jan 09 2026
NASDAQ.COM
Zentalis Pharmaceuticals' Azenosertib Set for Key Milestones in 2026
Jan 07 2026
NASDAQ.COM
Zentalis Pharmaceuticals Reveals Inducement Grants in Accordance with Nasdaq Listing Rule 5635(c)(4)
Nov 03 2025
Newsfilter
Zentalis Pharmaceuticals Set to Attend Upcoming Investor Conferences
Nov 03 2025
Newsfilter
Zentalis Pharmaceuticals to Showcase Four Azenosertib Posters at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Oct 13 2025
Newsfilter
Zentalis Pharmaceuticals Reveals Inducement Grants in Accordance with Nasdaq Listing Rule 5635(c)(4)
Oct 01 2025
Newsfilter
Biotech Stocks Soar in After-Hours Trading: CAPR and TMDX Top the List Following Trial News and Earnings Boost
Sep 09 2025
NASDAQ.COM
Zentalis Pharmaceuticals Names James B. Bucher, JD, as Chief Legal Officer and Corporate Secretary
Aug 26 2025
Newsfilter
Show More News
